Where does Sofregen Medical, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Sofregen Medical, Inc. ranks #43,191 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Sofregen Medical, Inc. hold?

Sofregen Medical, Inc. holds 6 US utility patents granted between 2020 and 2025, spanning 5 technology areas.

What is Sofregen Medical, Inc.'s Innovation Score?

Sofregen Medical, Inc. has an Innovation Score of 44.7 out of 100 (top 25% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Sofregen Medical, Inc. focus on?

Sofregen Medical, Inc.'s top technology area is C08K (Use of inorganic or non-macromolecular organic substances as compounding ingredients) with 5 patents, ranking #547 of 1,963 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Sofregen Medical, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Sofregen Medical, Inc..

What does claim depth mean for Sofregen Medical, Inc.'s patents?

Sofregen Medical, Inc.'s patents average 16.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Sofregen Medical, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Sofregen Medical, Inc.

USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C08K (Use of inorganic or non-macromolecular organic substances as compounding ingredients).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Sofregen ranks #43,191 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 5 technology areas.

#43,191
of 49,997 US assignees by volume: Top 25%
by Innovation Score (44.7/100): 16.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R43191 · US Corporation #43,191 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #43,191/49,997
PHOTO-FINISH Smiths Group
CPC-NARROW C08K · 5 areas
INNOV-PAR 44.7/100
CLAIMS-RICH 16.8 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Smiths Group PLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Sofregen’s 44.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (15%) Velocity 20.0 pts (45%) Breadth 7.9 pts (18%) Claim depth 10.1 pts (23%)

Qualcomm Incorporated · highest

85
Sofregen Medical · this assignee

45
3D Lighting… · lowest

7

What this shows Sofregen's Innovation Score is 44.7/100 (top 25% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Sofregen?

Each dot is one of Sofregen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Sofregen’s own 16.8 claims/patent is ABOVE the 16.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Sofregen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Sofregen's grants concentrate

Sofregen Medical, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 83.3% of grants classified under C08K (Use of inorganic or non-macromolecular organic substances as compounding ingredients). Peak complete grant year is 2023 (4 grants) versus a trough of 1 in 2020. By volume, Sofregen sits between Smiths Group PLC and Solace Systems, Inc..

Sofregen's three-year grant acceleration

Sofregen Medical, Inc. shows 4 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Smiths Group

6
Snap-on Equipment…

6
Soctronics

6
Soci

6
Softeye

6
Softbox Systems

6
Sogefi Air & Cool…

6
Solace Systems

6
Sofregen Medical ◀

6

What this shows Sofregen holds 6 patents at rank #43,291, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Sofregen

By rank, the assignees closest to #43,291 in granted patent volume.

Leaders in C08K (Use of inorganic or non-macromolecular organic substances…)

Other assignees with the most granted patents in Sofregen's primary technology class.

Sofregen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 25% higher than 75% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Sofregen Medical, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	16.7%
2023	4	66.7%
2025partial year	1	16.7%

Which technologies does Sofregen Medical, Inc. patent most?

C08K - Use of inorganic or non-macromolecular organic substances as compounding ingredients 5

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 5

C08L - Compositions OF Macromolecular Compounds 5

A61B - DIAGNOSIS; SURGERY; Identification 1

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Sofregen Medical, Inc.'s patent record in context - here's where to go next.

Sofregen Medical, Inc.'s lead technology class is C08K (Use of inorganic or non-macromolecular organic substances as compounding ingredients), 83.3% of its portfolio - see every assignee active in that class. Explore C08K
Ranked #43,191 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Sofregen Medical, Inc. against Smiths Group PLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.